LC
ALT icon

Lindbrook Capital’s Altimmune ALT Stock Holding History

Lindbrook Capital’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$15 Sell
3
-58
-95% -$367 ﹤0.01% 2772
2024
Q4 		$440 Sell
61
-23
-27% -$176 ﹤0.01% 2652
2024
Q3 		$516 Buy
+84
New +$569 ﹤0.01% 2654

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lindbrook Capital's ALT Position: Q1 2025 in Review

Lindbrook Capital reduced its Altimmune (ALT) stake by 95% in Q1 2025, selling an estimated $367 and leaving 3 shares worth $15. The position accounts for ﹤0.01% of the portfolio, ranked #2772.

Lindbrook Capital first reported a position in ALT in Q3 2024 and has held it in 3 quarters since. The position peaked at $516 in Q3 2024. 176 funds tracked by Wall St. Rank hold ALT as of Q1 2025.

  • Lindbrook Capital held 3 shares of Altimmune worth $15 as of Q1 2025.
  • Lindbrook Capital sold 58 Altimmune shares in Q1 2025, an estimated $367.
  • Altimmune made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2772 holding.
  • Lindbrook Capital first reported a position in Altimmune in Q3 2024 and has held it in 3 quarters since.
  • Lindbrook Capital's Altimmune position peaked at $516 in Q3 2024.
  • 176 funds tracked by Wall St. Rank held Altimmune as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.